As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

Novo Nordisk has told the world it expects patients to lose “at least 25%” of their body weight on its experimental drug CagriSema.It turns out the company was wrong.On Friday, Novo released the results of a large Phase 3 trial of the drug.

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late-stage clinical trial findings reported Friday.